Tandem Diabetes Care, Inc. Stock News

NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 9:15 AM EDT Company Participants John Sheridan - President, CEO & Director Leigh Vosseller - Executive VP, CFO & Treasurer Presentation Unknown Analyst All right. Good morning, everyone.

SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem t:slim Mobile App authorized by Health Canada for iPhone and Android Phones. The app will be available for Canadian customers later this year.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TANDEM DIABETES CARE, IN...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TANDEM DIABETES CARE, INC. (TNDM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TANDEM DIABETES CARE, INC. (TNDM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RE...

Downgrading Tandem Diabetes Care to sell after Q2 2025 earnings confirms core U.S. business weakness and deteriorating profitability. Intense competition from Insulet and Medtronic is eroding Tandem's market share, with rivals showing stronger growth and profitability. Management's credibility is under pressure, due to material guidance downgrades and reactive strategy, despite upcoming product...

Tandem Diabetes Care issued a voluntary correction for an insulin pump model due to a speaker malfunction that disrupts communication with glucose monitoring systems, potentially causing high blood sugar levels.